| | 和 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 601228 | 广州港 | 0.1280 | 96443.07 | -10.63 | 1407293.13 | 6.66 | | 301488 | 豪恩汽 | 1.1000 | 10091.18 | -11.15 | 140893.71 | 17.25 | | | 电 | | | | | | | 001324 | 长青科 | 0.4361 | 6018.00 | -16.41 | 46042.71 | -13.16 | | | 技 | | | | | | | 002535 | 林州重 | 0.1189 | 9534.40 | -18.47 | 168353.14 | -8.38 | | | 机 | | | | | | | 002075 | 沙钢股 | 0.0700 | 16258.29 | -27.75 | 1441626.09 | -7.69 | | | 份 | | | | | | | 002860 | 星帅尔 | 0.4700 | 14369.40 | -29.03 | 207 ...

2025年4月9日，阳光诺和(688621.SH)发布2024年年度报告。截至2025年4月08日，共有115个机构投资 者披露持有阳光诺和A股股份，合计持股量达1798.59万股，占阳光诺和总股本的16.06%。其中，前十 大机构投资者包括武汉新能实业发展有限公司、中国工商银行股份有限公司-富国天惠精选成长混合型 证券投资基金(LOF)、中国工商银行股份有限公司-融通健康产业灵活配置混合型证券投资基金、广州广 发信德一期健康产业投资企业(有限合伙)、招商银行股份有限公司-安信医药健康主题股票型发起式证券 投资基金、天津海达创业投资管理有限公司-广州正达创业投资合伙企业(有限合伙)、建信医疗健康行业 股票A、长城大健康混合A、中证2000、长城医疗保健混合A，前十大机构投资者合计持股比例达 13.66%。相较于上一季度，前十大机构持股比例合计下跌了4.84个百分点。 公募基金方面，本期较上一期持股增加的公募基金共计1个，即富荣福康混合A，持股增加占比小幅上 涨。本期较上一季度持股减少的公募基金共计4个，包括安信医药健康股票A、融通健康产业灵活配置 混合A/B、富国天惠成长混合(LOF)A/B、国投瑞银专精特新 ...

Core Viewpoint - The company, Yangguang Nuohuo, is a professional CRO providing comprehensive drug research and development services, focusing on innovative drug development and the growing demand in the CRO industry driven by favorable policies and market needs [4][10][11]. Company Overview - Yangguang Nuohuo is a CRO established in 2009, specializing in preclinical and clinical drug development services, with a strong emphasis on supporting domestic pharmaceutical companies in achieving innovation and import substitution [4][13]. - The company has a total of 3.66 million square meters of laboratory space, with 3.35 million square meters currently in use, and employs 1,556 staff, of which 84.7% are R&D personnel [13]. Business Model - The company operates on a commission basis, providing a range of services from drug discovery to clinical trials, and typically charges fees based on project milestones [5][6]. - Yangguang Nuohuo retains rights to share in sales revenues from drugs developed in collaboration with clients, enhancing its revenue potential [7]. Industry Situation - The global CRO market is projected to grow from $84.7 billion in 2023 to $96 billion in 2024, reflecting a year-on-year increase of approximately 13.3% [11]. - The domestic CRO market has expanded from 36.49 billion RMB in 2018 to 81.37 billion RMB in 2022, with expectations to reach 275.77 billion RMB by 2030, indicating a compound annual growth rate of 14% [12]. Technological and Policy Developments - The integration of AI in drug development processes is becoming increasingly significant, enhancing efficiency in drug discovery and clinical trials [18][19]. - Recent policies have shifted the focus from generic drug development to innovative drug research, creating opportunities for leading CROs to expand their services [16][17]. Financial Performance - In the latest reporting period, the company achieved a revenue of 1.078 billion RMB, a year-on-year increase of 15.7%, while net profit decreased by 7.59% to 169.01 million RMB [26]. - The proposed cash dividend distribution is 1.63 RMB per 10 shares, amounting to a total of approximately 17.81 million RMB, which represents 10.04% of the net profit attributable to shareholders [2]. Future Outlook - The company plans to continue increasing R&D investments, focusing on cutting-edge technologies and expanding its product pipeline to meet unmet clinical needs [49]. - The CRO industry is expected to see further consolidation, with leading firms enhancing their competitive edge through integrated service offerings [22][23].

Core Viewpoint - The company is set to engage in daily related transactions with its affiliates for the year 2025, which are deemed necessary for normal business operations and will not harm the interests of the company or its shareholders [9][10]. Summary by Sections Related Party Transactions - The company has disclosed its related party transactions, including expected amounts and categories, with specific affiliates such as Beijing Bai'ao Pharmaceutical Co., Ltd. and Jiangsu Yong'an Pharmaceutical Co., Ltd. [1][3][4][5][6]. - The expected transaction amounts are calculated based on the company's projected expenditures or revenues for similar business activities in 2024 [1]. Performance and Compliance - The affiliates involved in the transactions have good credit and financial conditions, ensuring their ability to fulfill contractual obligations without creating bad debts for the company [2]. - The company will sign contracts with related parties for the expected daily transactions in 2025, ensuring legal protection for performance [2][8]. Pricing Policy - The pricing policy for related party transactions is based on fair and just principles, using market prices as a reference. Agreements are made voluntarily and equitably [7]. Purpose and Impact - The anticipated related transactions are essential for the company's operational needs, aimed at consolidating market presence, enhancing operational capabilities, and promoting profit growth. The transactions are structured to avoid dependency on related parties [9][10]. Approval Process - The expected related party transactions for 2025 have been approved by the company's board and will be submitted for shareholder approval [10][21]. Financial Indicators - The company reported a significant increase in R&D investment, amounting to 171.94 million yuan in 2024, representing a 39.02% increase from 2023, with R&D expenses accounting for 15.94% of total revenue [46]. Competitive Advantages - The company has established a comprehensive drug development service model, enhancing its ability to meet diverse client needs and improve the success rate of drug development [38][39]. - The company has developed specialized core technology clusters in high-difficulty research areas, providing a competitive edge in the market [39][40]. Client Relationships - The company has built strong client relationships through integrated drug development services, serving approximately 1,000 pharmaceutical enterprises, which enhances customer loyalty and supports future business growth [45]. Regulatory Compliance - The company has adhered to relevant laws and regulations regarding fundraising and the use of raised funds, ensuring compliance and protecting shareholder interests [49]. Management Changes - The company has undergone changes in its board of directors, including the resignation of an independent director and the nomination of a new candidate, ensuring compliance with governance requirements [51][52].

一、募集资金基本情况 1、募集资金金额、资金到账时间 经中国证券监督管理委员会《关于同意北京阳光诺和药物研究股份有限公司首次公开发行股票注册的批 复》（证监许可【2021】1629号），同意公司首次公开发行股票的注册申请，公司获准向社会公开发行 人民币普通股20,000,000股。每股面值为1元，每股发行价格为26.89元，本次发行募集资金总额 537,800,000.00元。上述募集资金总额扣除发行费用70,618,507.55元（相关费用均为不含税金额）后，本 次公司公开发行新股的募集资金净额467,181,492.45元，民生证券股份有限公司已于2021年6月16日将扣 除相关承销保荐费（不含税）人民币47,402,000.00元后的余款人民币490,398,000.00元汇入公司募集资金 专户，大华会计师事务所（特殊普通合伙）对公司本次公开发行新股的资金到位情况进行了审验，并于 2021年6月17日出具了《验资报告》（大华验字[2021]000430号）。 2、 募集资金报告期内使用金额及当前余额 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688621 证券简称：阳光诺和 公告编号： ...

证券代码：688621 证券简称：阳光诺和 公告编号：2025-023 北京阳光诺和药物研究股份有限公司 关于提请股东大会授权董事会以简易程序 向特定对象发行股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 授权董事会根据《中华人民共和国公司法》《中华人民共和国证券法》《注 册管理办法》等有关法律法规和规范性文件的规定，对公司实际情况进行自查和 论证，确认公司是否符合以简易程序向特定对象发行股票的条件。 （二） 发行股票的种类、面值和数量 本次发行股票的种类为境内上市的人民币普通股（A 股），每股面值人民币 1.00 元。发行融资总额不超过人民币 3 亿元且不超过最近一年末净资产 20%，发 行的股票数量按照募集资金总额除以发行价格确定，不超过发行前公司股本总数 的 30%。 若公司股票在定价基准日至发行日期间发生送股、资本公积金转增股本或因 1 根据《上市公司证券发行注册管理办法》（以下简称"《注册管理办法》"） 《上海证券交易所上市公司证券发行上市审核规则》《上海证券交易所上市公司 证券发行与承销业务实施细则 ...

北京阳光诺和药物研究股份有限公司 审计报告 政旦志远审字第 2500026 号 (1 政旦志远(深圳)会计师事务所(特殊普通合伙) Zandar Certified Public Accountants LLP 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ucc.mof.gov.cn) 报告编码:粤25ZSU 北京阳光诺和药物研究股份有限公司 审计报告及财务报表 (2024年1月1日至 2024年12月31日止) | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 1 | 审计报告 | | 1-6 | | í í | 已审财务报表 | | | | | 合并资产负债表 | | 1-2 | | | 合并利润表 | | 3 | | | 合并现金流量表 | | 4 | | | 合并股东权益变动表 | | 5-6 | | | 母公司资产负债表 | | 7-8 | | | 母公司利润表 | | 9 | | | 母公司现金流量表 | | 10 | | | 母公司股东权益变动表 | | 11-12 | | | 财务报表附注 | | 1-88 | ZANDAR ...

民生证券股份有限公司 关于北京阳光诺和药物研究股份有限公司 2024 年持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法 律、法规的规定，民生证券股份有限公司（以下简称"民生证券"、"保荐机构"） 作为北京阳光诺和药物研究股份有限公司（以下简称"阳光诺和"、"公司"） 首次公开发行股票并在科创板上市的持续督导保荐机构，负责阳光诺和上市后的 持续督导工作，并出具本年度持续督导跟踪报告。 | 序号 | 工作内容 | 实施情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作制度，并针 对具体的持续督导工作制定相应的工作计划。 | 保荐机构已建立健全并有效执行 了持续督导制度，并制定了相应 | | | | 的工作计划。 | | | 根据中国证监会相关规定，在持续督导工作开 始前与上市公司或相关当事人签署持续督导 | 保荐机构已与阳光诺和签订保荐 协议，该协议明确了双方在持续 | | 2 | 协议，明确双方在持续督导期间的权利义务， | 督导期间的权利和义务，并已报 ...

民生证券股份有限公司 关于北京阳光诺和药物研究股份有限公司 及子公司申请综合授信额度及担保额度预计的核查意见 民生证券股份有限公司（以下简称"民生证券"、"保荐机构"）作为北京阳 光诺和药物研究股份有限公司（以下简称"阳光诺和"、"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管 指引第 1 号—规范运作》《科创板上市公司持续监管办法（试行）》等相关规定， 民生证券对阳光诺和及子公司申请综合授信额度及担保额度预计事项进行了审 慎核查，发表如下核查意见： 一、本次综合授信的基本情况 （一）公司及子公司拟申请银行授信情况 公司及子公司拟向银行申请合计不超过 137,000.00 万元（含本数）的授信额 度，授信期限为自股东大会决议通过之日起 12 个月内有效，在授信期限内，授 信额度可循环使用。 | 序号 | 借款方 | 拟申请授信额度（万元） | | --- | --- | --- | | 1 | 阳光诺和 | 120,000.00 | | 2 | 阳光德美 | 4,000.00 | | 3 | ...